Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized

Executive Summary

Office of Prescription Drug Promotion seemed to expand its focus in issuing 11 letters last year.


Related Content

Pre-approval Promotion: Corporate Communications May Draw US FDA Scrutiny
US FDA Reprimands Arog Pharmaceuticals For Promo Of Investigational AML Drug
US FDA Calls Foul On CSL Behring Hemophilia Drug Promo
DTC Trouble: ‘Attention-Grabbing Visuals’ Undermine Risk Info, FDA Tells Celgene, Sanofi
FDA’s Promotional Enforcement Still Playing It Safe
Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids
FDA's Decline In Promotion Enforcement Highlighted By Celator Booth Letter
Chiasma Looks Ahead To First Approval With "Revolutionary" Technology Opportunity
FDA's Rx Promotion Citation Drought Continued In 2015
FDA Makes Broad Concessions In Settling Pacira Promotion Suit


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts